10338 studies found for:    NCI
Show Display Options
Download search resultsDownload the search results for:
NCI (10338 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Bronchoalveolar Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
2 Completed
Has Results
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
Conditions: Barrett Esophagus;   Esophageal Cancer
Interventions: Drug: acetylsalicylic acid;   Drug: esomeprazole magnesium;   Other: placebo
3 Completed Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Intervention: Drug: alvocidib
4 Active, not recruiting
Has Results
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate
5 Recruiting Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: entinostat;   Drug: lapatinib ditosylate;   Biological: trastuzumab;   Other: laboratory biomarker analysis
6 Completed Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
Condition: Lymphoma
Interventions: Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ganciclovir;   Drug: valganciclovir;   Drug: zidovudine
7 Completed Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Localized Malignant Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis
8 Completed
Has Results
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
9 Completed
Has Results
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: vorinostat;   Procedure: conventional surgery
10 Active, not recruiting Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
11 Completed Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
Conditions: Lip and Oral Cavity Cancer;   Oropharyngeal Cancer;   Stage 0 Lip and Oral Cavity Cancer;   Stage 0 Oropharyngeal Cancer;   Tongue Cancer
Interventions: Biological: Ad5CMV-p53 gene;   Other: laboratory biomarker analysis
12 Completed Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Conditions: Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway Glioma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: pazopanib hydrochloride;   Other: pharmacological study
13 Recruiting MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Adult Brain Tumor;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: TORC1/2 inhibitor MLN0128;   Biological: bevacizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Terminated SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: semaxanib;   Other: laboratory biomarker analysis
15 Completed UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 7-hydroxystaurosporine;   Drug: gemcitabine hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Active, not recruiting Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: daunorubicin hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Procedure: bone marrow aspiration;   Procedure: biopsy;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: questionnaire administration
17 Completed Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: gefitinib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: quality-of-life assessment
18 Completed Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Radiation: radiation therapy;   Drug: oxaliplatin;   Drug: fluorouracil;   Drug: gemcitabine hydrochloride
19 Completed Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Dietary Supplement: garlic;   Drug: docetaxel
20 Active, not recruiting Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Conditions: Borderline Ovarian Surface Epithelial-stromal Tumor;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Cavity Cancer;   Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor
Interventions: Drug: selumetinib;   Other: pharmacological study;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years